Maresin 1 促进根尖周病变炎症消退与骨愈合
本研究在小鼠根尖周炎模型中经根管给予 MaR1 或溶剂,用 micro-CT 和组织学评估病变与骨量,并通过 Treg 清除实验探索机制。MaR1 显著缩小病变、提高骨体积分数、减少炎症细胞和粪肠球菌,提示其可促进炎症消退与骨修复。
要点
- MaR1 经根管给药可显著缩小小鼠根尖周病变。
- MaR1 提高骨体积/总体积比值并减轻骨量丢失。
- MaR1 减少炎症细胞浸润及粪肠球菌。
核心结论
- MaR1 有望用于慢性根尖周炎治疗,兼具炎症消退、保骨和减少粪肠球菌的作用,并支持免疫调节与组织修复。
研究设计与样本
- 小鼠经牙髓暴露建立慢性根尖周炎模型,随机接受根管内 MaR1 或溶剂给药。
- 采用 micro-CT 分析病变大小与骨体积变化,HE 染色评估炎症细胞浸润,二代测序分析微生物多样性。
- 通过 Foxp3eGFP/IL17 转基因小鼠白喉毒素诱导清除 Tregs,进一步探索 Tregs 的作用。
- 统计分析采用参数方法,经 Shapiro-Wilk 检验确认正态性,并行方差分析及 Tukey 事后检验和 Bonferroni 校正 t 检验,P < 0.05 为显著。
主要发现
- 二维分析中对照组与病变组差异显著,支持实验模型有效。
- MaR1 治疗显著缩小病变(P < 0.0001)。
- MaR1 组骨体积/总体积比值显著高于溶剂组(P < 0.05)。
- 病变组骨量减少,MaR1 治疗显著减轻骨丢失(P < 0.05)。
- MaR1 组炎症细胞数显著少于溶剂组(P < 0.05),并减少粪肠球菌。
临床怎么用
- 提示根管内应用 MaR1 可能成为慢性根尖周炎促进炎症消退与骨愈合的辅助策略。
- 其减少粪肠球菌的作用可能有助于控制持续性感染。
局限性
- 证据来自小鼠模型,尚未在人体验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic apical periodontitis (CAP) is a persistent inflammatory condition caused by microbial infections in the root canal system, leading to bone loss and tissue damage. In this study, we tested the hypothesis that maresin 1 (MaR1), a specialized proresolving mediator, facilitates inflammatory resolution and promotes bone healing in CAP. We developed a CAP model in mice through pulp exposure. Animals received intracanal administration of either MaR1 or a vehicle. Micro-computed tomography (micro-CT) was used to analyze lesion size and bone volume changes. Inflammatory cell infiltration was assessed in hematoxylin and eosin-stained sections, and microbial diversity was analyzed using next-generation sequencing. The role of regulatory T cells (Tregs) was further explored through diphtheria toxin-induced depletion of Tregs in Foxp3eGFP/IL17 transgenic mice. All statistical analyses were performed using parametric methods, as confirmed by the Shapiro-Wilk test for data normality. Analysis of variance with Tukey's post hoc and Bonferroni-corrected t tests was applied. P < 0.05 was considered significant. In 2-dimensional analyses, a significant difference was observed between the control and lesion groups, supporting the validity of the experimental model. MaR1 treatment significantly reduced lesion size (P < 0.0001). The bone volume/total volume ratio was significantly higher in the MaR1 group than in the vehicle group (P < 0.05). Bone mass was reduced in the lesion group, whereas MaR1 treatment significantly alleviated this loss (P < 0.05). The number of inflammatory cells was significantly lower in the MaR1 group compared to the vehicle group (P < 0.05). MaR1 also reduced Enterococcus faecalis, a key pathogen in persistent infections. This study highlights MaR1 as a promising treatment for chronic apical periodontitis, showing benefits in resolving inflammation, preserving bone, and reducing E. faecalis. Unlike conventional therapies, MaR1 supports immune modulation and tissue repair.
引用
- Demir E, İlgenli I, Guney Z, et al. Maresin 1 Resolves Inflammation and Aids Bone Healing in Periapical Lesions. J Dent Res. 2025. PMID: 41408494. doi:10.1177/00220345251399558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。